Gene: TOM1L2
Official Full Name: target of myb1 like 2 membrane trafficking proteinprovided by HGNC
Gene Summary: This gene belongs to a small gene family whose members have an N-terminal VHS domain followed by a GAT domain; domains which typically participate in vesicular trafficking. The canonical protein encoded by this gene also has a C-terminal clathrin binding motif. This protein has been shown to interact with Tollip, clathrin and ubiquitin and is thought to play a role in endosomal sorting. This gene resides in the 3.7 Mb deletion of chromosome region 17p11.2 that is associated with Smith-Magenis syndrome. Alternative splicing results in multiple transcript variants encoding distinct proteins. [provided by RefSeq, Apr 2017]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO23977 | TOM1L2 Knockout cell line (HeLa) | Human | TOM1L2 | 1:3~1:6 | Negative | Online Inquiry |
KO23978 | TOM1L2 Knockout cell line (HCT 116) | Human | TOM1L2 | 1:2~1:4 | Negative | Online Inquiry |
KO23979 | TOM1L2 Knockout cell line (HEK293) | Human | TOM1L2 | 1:3~1:6 | Negative | Online Inquiry |
KO23980 | TOM1L2 Knockout cell line (A549) | Human | TOM1L2 | 1:3~1:4 | Negative | Online Inquiry |
TOM1L2 Gene Knockout Cell Lines represent a pioneering advancement in gene editing technologies, specifically designed to facilitate the study of the TOM1L2 gene's biological functions and implications in various pathways. These highly specialized cell lines have been engineered using CRISPR-Cas9 technology to disrupt the TOM1L2 gene, which is critical for understanding its role in cellular processes such as endocytosis, apoptosis, and immune responses.
The primary function of TOM1L2 involves regulating the trafficking of cellular proteins and vesicles, making its study pivotal in elucidating mechanisms of receptor recycling and signal transduction pathways. By creating knockout models, researchers can examine the consequences of TOM1L2 loss on cellular physiology and disease models, which is instrumental in cancer research, autoimmune disorders, and neurodegenerative conditions.
From a scientific perspective, TOM1L2 Gene Knockout Cell Lines offer vast applications in both basic research and potential clinical scenarios, including drug discovery and therapeutic targeting. The ability to manipulate these specific gene functions enhances the understanding of complex biological systems and opens avenues for innovative treatment strategies.
Compared to traditional knockdown methods, our TOM1L2 Gene Knockout Cell Lines provide a more permanent genetic alteration, thereby ensuring stability and reproducibility in experiments. Additionally, the specificity and efficiency of our knockout models minimize off-target effects, delivering more reliable and actionable data to researchers.
The value of TOM1L2 Gene Knockout Cell Lines lies in their potential to accelerate the pace of discovery in cellular biology and therapeutics. For researchers and clinicians aiming to deepen their insights into gene function and disease mechanisms, these cell lines provide a crucial tool for innovative exploration.
Our company specializes in the development of advanced biological products and has a strong track record of delivering high-quality, precision-engineered solutions tailored to the needs of the scientific community. Through continuous investment in cutting-edge technology and research, we commit to empowering researchers and advancing scientific knowledge.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.